SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Schunkert, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schunkert, H.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Heart Failure
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

The importance of early intervention in CHF — signs and symptom relief

Heribert Schunkert

University of Regensburg, Regensburg, Germany, heribert.schunkert@klinik

Effective treatments of congestive heart failure (CHF) must not only reduce mortality, but should also reduce the severity of the signs and symptoms of the syndrome, as these can have a major impact on quality of life. Early intervention can help to make everyday activities easier for patients with CHF and may slow disease progression. This review provides an overview of the efficacies of various therapies in improving the signs and symptoms of CHF, with particular reference to recent data from randomised, double-blind studies of patients receiving the AT 1-receptor blocker, candesartan cilexetil.

Key Words: congestive heart failure • symptom relief • angiotensin II type 1-receptor blockers • candesartan cilexetil

References

  • Francis GS Neurohumoral mechanisms involved in congestive heart failure. Am J Cardiol 1985;55:15A-21A.[Medline] [Order article via Infotrieve]
  • Schunkert H., Sadoshima J., Cornelius T. et al. Angiotensin II-induced growth responses in isolated adult rat hearts. Evidence for load-independent induction of cardiac protein synthesis by angiotensin II. Circ Res 1995;76:489-97.[Abstract/Free Full Text]
  • Jacobi J., Schlaich MP, Delles C., Schobel HP, Schmieder RE Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure. Am J Hypertens 1999;12 (4 Part 1):418-22.[Web of Science][Medline] [Order article via Infotrieve]
  • Pratt RE Angiotensin II and the control of cardiovascular structure. J Am Soc Nephrol 1999;10 Suppl 11:S120-8.[Web of Science][Medline] [Order article via Infotrieve]
  • Schunkert H., Dzau VJ,Tang SS, Hirsch AT,Apstein CS, Lorell BH Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation. J Clin Invest 1990;86:1913-20.
  • Koilpillai C., Quinones MA, Greenberg B. et al. Relation of ventricular size and function to heart failure status and ventricular dysrhythmia in patients with severe left ventricular dysfunction. Am J Cardiol 1996;77:606-11.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).NEnglJMed 1987;316:1429-35.[Abstract]
  • The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.[Abstract]
  • Pouleur H., Konstam MA, Benedict CR et al. Progression of left ventricular dysfunction during enalapril therapy: relationship with neurohormonal reactivation. Circulation 1993;88 Suppl I:I-293A.
  • Aldigier JC, Huang H., Dalmay F. et al.Angiotensin-converting enzyme inhibition does not suppress plasma angiotensin II increase during exercise in humans. J Cardiovasc Pharmacol 1993;21:289-95.[Web of Science][Medline] [Order article via Infotrieve]
  • Holmer SR, Hense HW, Danser AH, Mayer B., Riegger GA, Schunkert H. Beta adrenergic blockers lower renin in patients treated with ACE inhibitors and diuretics. Heart 1998;80:45-8.[Abstract/Free Full Text]
  • Schunkert H. Ingelfinger JR, Hirsch AT et al. Feedback regulation of angiotensin converting enzyme activity and mRNA levels by angiotensin II. Circ Res 1993;72:312-8.[Abstract/Free Full Text]
  • Jorde UP, Ennezat PV, Lisker J. et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 2000; 101:844-6.[Abstract/Free Full Text]
  • Cohn JN Preventing congestive heart failure. Am Fam Physician 1998;57:1901-4.[Web of Science][Medline] [Order article via Infotrieve]
  • Brater DC Diuretic therapy. N Engl J Med 1998;339:387-95.[Free Full Text]
  • Cody RJ, Kubo SH, Pickworth KK Diuretic treatment for the sodium retention of congestive heart failure. Arch Intern Med 1994;154:1905-14.[Abstract/Free Full Text]
  • Knowlton KU, Michel MC, Itani M. et al. The alpha 1A-adrenergic receptor subtype mediates biochemical, molecular, and morphologic features of cultured myocardial cell hypertrophy. J Biol Chem 1993;268:15374-80.[Abstract/Free Full Text]
  • Simons M., Downing SE Coronary vasoconstriction and catecholamine cardiomyopathy. Am Heart J 1985;109:297-304.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Billman GE, Castillo LC, Hensley J., Hohl CM,Altschuld RA Beta2-adrenergic receptor antagonists protect against ventricular fibrillation: in vivo and in vitro evidence for enhanced sensitivity to beta2-adrenergic stimulation in animals susceptible to sudden death. Circulation 1997;96:1914-22.[Abstract/Free Full Text]
  • Kaumann AJ, Sanders L. Both beta 1- and beta 2-adrenoceptors mediate catecholamine-evoked arrhythmias in isolated human atrium. Naunyn Schmiedebergs Arch Pharmacol 1993;348:536-40.[Web of Science][Medline] [Order article via Infotrieve]
  • Barr CS, Lang CC, Hanson J.,Arnott M., Kennedy N., Struthers AD Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76: 1259-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Rocha R., Chander PN, Khanna K., Zuckerman A., Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998;31 (1 Part 2):451-8.[Abstract/Free Full Text]
  • Weber KT, Villarreal D. Aldosterone and antialdosterone therapy in congestive heart failure. Am J Cardiol 1993;71:3A-11A.[Medline] [Order article via Infotrieve]
  • Pitt B., Zannad F., Remme WJ, Cody RJ Spironolactone appears beneficial regardless of ejection fraction: the RALES Trial. Circulation 1999;100 Suppl 1:I-298.
  • Akera T., Baskin SI, Tobin T., Brody TM Ouabain: temporal relationship between the inotropic effect and the in vitro binding to, and dissociation from, (Na+ + K+)-activated ATPase. Naunyn Schmiedebergs Arch Pharmacol 1973;277:151-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Thames MD Acetylstrophanthidin-induced reflex inhibition of canine renal sympathetic nerve activity mediated by cardiac receptors with vagal afferents. Circ Res 1979;44:8-15.[Abstract/Free Full Text]
  • Ferguson DW, Berg WJ, Sanders JS, Roach PJ, Kempf JS, Kienzle MG Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. Circulation 1989;80:65-77.[Abstract/Free Full Text]
  • Torretti J.,Hendler E.,Weinstein E., Longnecker RE, Epstein FH Functional significance of Na-K-ATPase in the kidney: effects of ouabain inhibition. Am J Physiol 1972;222:1398-405.[Free Full Text]
  • The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.[Abstract/Free Full Text]
  • Packer M., O'Connor CM, Ghali JK et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group.NEnglJMed 1996;335:1107-14.[Abstract/Free Full Text]
  • Cohn JN, Ziesche S., Smith R. et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation 1997;96:856-63.[Abstract/Free Full Text]
  • Levine TB The design of the Mortality Assessment in Congestive Heart Failure Trial (MACH-1, mibefradil). Clin Cardiol 1997;20:320-6.[Web of Science][Medline] [Order article via Infotrieve]
  • Elkayam U. Presentation of the results of the MACH-1 Trial. XXI Congress of the European Society of Cardiology, 25 August, 1998.
  • Packer M., Cohn JN, Abraham WT et al., on behalf of the Membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure. Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999; 83 (2A):27A-28A.[CrossRef]
  • Cohn JN, Johnson G., Ziesche S. et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325: 303-10.[Abstract]
  • The Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988;259: 539-44.[Abstract/Free Full Text]
  • Packer M., Kessler PD, Gottlieb SS Adverse effects of converting-enzyme inhibition in patients with severe congestive heart failure: pathophysiology and management. Postgrad Med J 1986;62 Suppl 1:179-82.[Free Full Text]
  • Israili ZH, Hall WD Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992;117:234-42.[Abstract/Free Full Text]
  • Cibis II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • The International Steering Committee. Rationale, design, and organization of the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF). Am J Cardiol 1997;80 (9B):54J-58J.[CrossRef][Medline] [Order article via Infotrieve]
  • Colucci WS, Packer M., Bristow MR et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation 1996;94:2800-6.[Abstract/Free Full Text]
  • Patterson JH, Adams KF Jr, Applefeld MM, Corder CN, Masse BR Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Torsemide Investigators Group. Pharmacotherapy 1994;14:514-21.[Web of Science][Medline] [Order article via Infotrieve]
  • Parker JO The effects of oral ibopamine in patients with mild heart failure - a double blind placebo controlled comparison to furosemide.The Ibopamine Study Group. Int J Cardiol 1993;40:221-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Francis GS, Benedict C., Johnstone DE et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724-9.[Abstract/Free Full Text]
  • Packer M., Lee WH, Medina N., Yushak M., Kessler PD Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med 1987;106:346-54.[Abstract/Free Full Text]
  • Richardson A., Bayliss J., Scriven AJ, Parameshwar J., Poole-Wilson PA, Sutton GC Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure. Lancet 1987;2:709-11.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sherman LG, Liang CS, Baumgardner S., Charuzi Y., Chardo F., Kim CS Piretanide, a potent diuretic with potassium-sparing properties, for the treatment of congestive heart failure. Clin Pharmacol Ther 1986;40:587-94.[Web of Science][Medline] [Order article via Infotrieve]
  • Cody RJ, Franklin KW, Laragh JH Postural hypotension during tilt with chronic captopril and diuretic therapy of severe congestive heart failure. Am Heart J 1982;103 (4 Part 1):480-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Massie B., Kramer B., Haughtom F. Postural hypotension and tachycardia during hydralazine-isosorbide dinitrate therapy for chronic heart failure. Circulation 1981;63:658-64.[Abstract/Free Full Text]
  • Wilson JR, Reichek N., Dunkman WB, Goldberg S. Effect of diuresis on the performance of the failing left ventricle in man. Am J Med 1981;70:234-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Steiness E., Olesen KH Cardiac arrhythmias induced by hypokalaemia and potassium loss during maintenance digoxin therapy. Br Heart J 1976;38:167-72.[Abstract/Free Full Text]
  • Granger G., Ertl G., Kuch J. et al., on behalf of the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Investigators.A randomized trial evaluating tolerability of candesartan cilexetil for patients with congestive heart failure and intolerance to angiotensin converting enzyme inhibitors. Eur Heart J 1998;19 Suppl:133.
  • McKelvie RS,Yusuf S., Pericak D. et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) Pilot Study.The RESOLVD Pilot Study Investigators. Circulation 1999;100:1056-64.[Abstract/Free Full Text]
  • Riegger GA, Bouzo H., Petr P. et al. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators. Circulation 1999;100:2224-30.[Abstract/Free Full Text]
  • Takeda, 1999. Study of the 3-month haemodynamic effects of 2 mg, 4 mg, and 16 mg candesartan cilexetil (TCV-116) in patients with impaired left ventricular function (heart failure - NYHA class II/III). A double-blind, randomised, placebo-controlled, multi-centre study. (Data on file)
  • Pitt B., Segal R., Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet 1997;349:747-52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pitt B., Poole-Wilson PA, Segal R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cohn JN Improving outcomes in congestive heart failure: Val-HeFT. Valsartan in Heart Failure Trial. Cardiology 1999;91 Suppl 1:19-22.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Swedberg K., Pfeffer M., Granger C. et al. Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity (CHARM): rationale and design. Charm Programme Investigators. J Card Fail 1999;5:276-82.[CrossRef][Medline] [Order article via Infotrieve]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 1, No. 1 suppl, 17-23 (2000)
DOI: 10.3317/jraas.2000.028
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Schunkert, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schunkert, H.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Heart Failure
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement